Research Progress of Axl Inhibitors-Reference-Cited by-同舟云学术

Research Progress of Axl Inhibitors

Published:2019-09-03 Issue:15 Volume:19 Page:1338-1349
ISSN:1568-0266
Container-title:Current Topics in Medicinal Chemistry
language:en
Short-container-title:CTMC

Author:

Sun Zhi-Gang¹,Liu Jian-Hua¹,Zhang Jin-Mai²,Qian Yong³

Affiliation:

1. Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, China

2. Room 205, BIO-X white house, Shanghai Jiao Tong University, No.1954 Huashan Road, Shanghai 200030, China

3. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Road, Nanjing 210023, China

Abstract

Axl, a Receptor Tyrosine Kinase (RTK) belonging to the TAM (Axl, Mer, Tyro3) family, participates in many signal transduction cascades after mostly being stimulated by Growth arrestspecific 6(Gas6). Axl is widely expressed in many organs, such as macrophages, endothelial cells, heart, liver and skeletal muscle. Over-expression and activation of Axl are associated with promoting chemotherapy resistance, cell proliferation, invasion and metastasis in many human cancers, such as breast, lung, and pancreatic cancers. Therefore, the research and development of Axl inhibitors is of great significance to strengthen the means of cancer treatment, especially to solve the problem of drug resistance. Axl inhibitors have attracted more and more researchers' attention in recent years. This review discusses the research progress of Axl inhibitors in recent years.

Funder

Linyi Science and Technology Innovation and Development Project

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference150 articles.

1. Mathew A.; George P.S.; K M, J.K.; Vasudevan, D.; James, F.V. Transition of cancer in populations in India. Cancer Epidemiol [http://dx.doi.org/10.1016/j.canep.2018.12.003]. [PMID: 30537646].2019,58,111-120

2. Ferlay J.; Colombet M.; Soerjomataram I.; Dyba T.; Randi G.; Bettio M.; Gavin A.; Visser O.; Bray F.; Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer [http://dx.doi.org/10.1016/j.ejca.2018.07.005]. [PMID: 30100160].2018,103,356-387

3. Allen B.C.; Crump K.S.; Shipp A.M.; Correlation between carcinogenic potency of chemicals in animals and humans. Risk Anal [http://dx.doi.org/10.1111/j.1539-6924.1988.tb01193.x]. [PMID: 3266676].1988,8(4),531-544

4. Hecht S.S.; Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg [http://dx.doi.org/10.1007/s00423-006-0111-z]. [PMID: 17031696].2006,391(6),603-613

5. Alexandrov L.B.; Ju Y.S.; Haase K.; Van Loo P.; Martincorena I.; Nik-Zainal S.; Totoki Y.; Fujimoto A.; Nakagawa H.; Shibata T.; Campbell P.J.; Vineis P.; Phillips D.H.; Stratton M.R.; Mutational signatures associated with tobacco smoking in human cancer. Science [http://dx.doi.org/10.1126/science.aag0299]. [PMID: 27811275].2016,354(6312),618-622

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AXL receptor as an emerging molecular target in colorectal cancer;Drug Discovery Today;2024-06

2. Receptor Tyrosine Kinase AXL Regulates c-Myc to Participate in Immune Escape of Endometrial Cancer Cells;J BIOL REG HOMEOS AG;2023

3. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors;Acta Pharmaceutica Sinica B;2023-12

4. Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study;Investigational New Drugs;2023-03-09

5. Recent Developments of Flavonoids with Various Activities;Current Topics in Medicinal Chemistry;2022-02